BiotechTube

AMG 786

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity

Trial Timeline

Jul 26, 2022 → Aug 21, 2023

NCT ID
NCT05406115

About AMG 786

AMG 786 is a phase 1 stage product being developed by Amgen for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05406115. Target conditions include Obesity.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05406115Phase 1Completed

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
52
MK0557MerckPhase 3
77
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
52
TirzepatideEli LillyPhase 2
52
exenatide + PlaceboEli LillyApproved
85
BrenipatideEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
TERN-601Terns PharmaceuticalsPhase 2
49
MBX 4291 + PlaceboMBX BiosciencesPhase 1
28
PG-102Rani TherapeuticsPhase 1
25
Orforglipron + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide + PlaceboEli LillyPhase 1
33
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
52
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
33
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
44
TirzepatideEli LillyApproved
85
Adenosine + RegadenosonAstellas PharmaPre-clinical
23
Micafungin + MicafunginAstellas PharmaApproved
85
MicafunginAstellas PharmaApproved
85

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84